Dr. Levis on the Ideal Use of Quizartinib in FLT3-ITD AML
Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the ideal way to use quizartinib to treat a patient with an FLT3-ITD mutation in acute myeloid leukemia (AML).
The ideal way to use a FLT3 inhibitor is to introduce it upfront with induction therapy in a newly diagnosed patient with FLT3-ITD AML, Levis says. Studies using FLT3 inhibitors that are not as effective still show a considerable amount of efficacy with this procedure.
Patients should be treated into remission and until the patient can receive an allogeneic transplant and then a FLT3 inhibitor. Levis says this method could lead to a quantum shift in the survival of patients with this disease.